vTv Therapeutics Inc (VTVT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$21.74-9.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VTVT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 1 guided quarters · 0.0% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026.
Stated in 2 of 2 supplied quarters. Management reported: “The Company expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026.” “The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026.”
“The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026.”
Based on its current cash position at the end of the second quarter of 2026, vTv expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout.
Stated in 2 of 2 supplied quarters. Management reported: “Based on its current cash position at the end of the second quarter of 2026, vTv expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout.” “vTv expects its current cash position to be sufficient to fund operations through the anticipated CATT1 topline data readout, positioning the Company to reach this key value inflection point with cash currently on hand.”
“Based on its current cash position at the end of the second quarter of 2026, vTv expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout.”
“vTv expects its current cash position to be sufficient to fund operations through the anticipated CATT1 topline data readout, positioning the Company to reach this key value inflection point with cas…”
In the fourth quarter of 2026, the Company also plans to host a Key Opinion Leader (KOL) event focused on T1D, the burden of managing hypoglycemia without compromising glycemic control, and cadisegli…
Stated in 1 of 2 supplied quarters. Management reported: “In the fourth quarter of 2026, the Company also plans to host a Key Opinion Leader (KOL) event focused on T1D, the burden of managing hypoglycemia without compromising glycemic control, and cadisegliatin’s potential to address this significant unmet need.”
“In the fourth quarter of 2026, the Company also plans to host a Key Opinion Leader (KOL) event focused on T1D, the burden of managing hypoglycemia without compromising glycemic control, and cadisegli…”
Preserve cash and cash equivalents to ensure funding of operations through anticipated Phase 3 topline data readout in late 2026.
Initiate Phase 2a Hybrid CATT1 trial before year-end 2026 to evaluate cadisegliatin in T1D patients using hybrid closed-loop insulin delivery systems.
Over the trailing year it converted -0.63x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 34% of the time over the next year (vs 53% for the rest of the cohort, n=2525).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.